There is no cure for HIV that works for people in general. Daily antiretroviral therapy (ART) keeps the virus under control, and the CDC says people who keep an undetectable viral load will not pass HIV to partners through sex. A small number of people, about ten by April 2026 by one research count, are considered cured or in long-term remission after stem-cell transplants. Those transplants were given to treat life-threatening blood cancers. They are dangerous and are not a treatment for HIV itself. Most of today's progress is about taking medicine less often, for both treatment and prevention. Our view: a cure for everyone will need to clear or permanently silence the virus that hides in resting immune cells. Antibody trials have delayed the virus's return after stopping treatment, but this is still research.
This is Cure Checker's editorial assessment of published evidence, not medical advice. Care decisions belong with an HIV care team.
Please read first. This is an AI-generated hypothesis, written by Cure Checker's AI from published research. It is speculation, not an established finding. It is not a recommendation, not a prediction that a cure exists, and not medical advice. No doctors or scientists have reviewed it, and it may be wrong. Never start, stop, change or delay any treatment because of it. Talk with your HIV care team.
Could "stem-like" HIV-fighting killer T cells be the missing link that decides whether antibodies lead to lasting remission? If a blood test that does not yet exist for this use could measure them, a supervised trial could test whether strengthening these cells first, then giving long-acting antibodies, keeps the virus away longer, including in people who started treatment late.
What would prove it wrong: if stem-like T-cell levels measured before a pause do not predict who stays in control in a larger randomized trial, or if raising them does not delay the virus's return.
Hypothesis written October 6, 2026. Cure Checker's AI will revisit it when major new evidence appears.
Newest first. Updated each morning as results, trial launches and papers are published.
In 12 people without HIV, one shot of a new long-acting mix of lopinavir, ritonavir and tenofovir (TLC-ART 101) kept lopinavir detectable for about two months. But one person had anaphylaxis (a severe allergic reaction) and four others had milder allergic reactions, and ritonavir was not prolonged. The authors say the allergy cause must be understood before further development. Early safety study; not a treatment option.
In a cohort of 3,349 adults in Spain who switched from daily pills to cabotegravir plus rilpivirine injections, followed a median of 25 months, 95.5% had suppressed virus and 89.0% were still on the injections. Confirmed treatment failure occurred in 28 people (0.8%), mostly within the first 12 months, and 19 of those 28 developed drug resistance. Treatment-limiting injection-site reactions occurred in 2.4%. This is an observational cohort with no comparison group.
In a Phase 3b open-label trial of 537 adults in Kenya, South Africa and Uganda whose HIV was suppressed but who had trouble sticking to daily pills, injections of cabotegravir plus rilpivirine every 8 weeks kept the virus below 50 copies/mL in 91.0% at week 48, versus 89.2% on daily dolutegravir-based pills, which met the study's noninferiority goal. Confirmed treatment failure occurred in 5 people (1.9%) on injections and none on pills. Serious side effects were 4.1% vs 3.0%. The trial was funded by Johnson & Johnson and did not test for drug resistance at the start.
In an open-label Phase 3 study of 639 adults who switched to the lower approved islatravir dose, 92.2% had HIV below 50 copies/mL at week 96 and 3 people (0.5%) had a confirmed rebound above 200 copies/mL. Side effects the researchers linked to the drug occurred in 3.0%, and 0.9% stopped because of side effects. There was no comparison group, and Merck employees are among the authors.
In 114 adults with HIV already controlled on treatment, switching to a once-daily two-drug pill combination (doravirine plus raltegravir) led to one virus rebound by week 48 (1.3%) in the switch group and none in the delayed-switch group; no more rebounds were seen through week 96. It was a small, open-label Phase 2 study, so it supports feasibility but is not proof this swap suits everyone.
In a placebo-controlled Phase 2b trial in people with HIV and extra central body fat (lipohypertrophy), 80 people (39 on semaglutide, 41 on placebo) were followed to week 56, 24 weeks after the 32-week treatment ended. After stopping, people who had taken semaglutide regained weight, belly fat and insulin resistance. Some of the weight, BMI and waist loss was still there compared with the start. The authors say ongoing treatment is likely needed to keep the benefit. This is about body fat in people with HIV, not HIV itself.
In 39 people who had a lymph node removed, HIV-infected cells fell quickly after starting treatment, both on two-drug dolutegravir/lamivudine and on a three-drug regimen. Mass spectrometry imaging showed the drugs reached lymph node tissue near infected cells. The trial's main goal, change in HIV DNA in blood cells, was similar in both groups. This looks at where the drugs go; it is not a cure.
The U.S. government HIV treatment panel posted a major update to its adult and adolescent guidelines, revising the "what to start" sections and the advice on optimizing treatment once the virus is controlled, among others. The panel said it is still reviewing the newly approved Bixlenvo for a future update. Guidelines are for clinicians; talk with your own HIV provider.
Gilead said it extended royalty-free licenses with six generic makers to cover an investigational once-a-year lenacapavir shot in 120 high-incidence countries, ahead of results from the ongoing Phase 3 PURPOSE 365 trial. This is a company announcement. There are no results yet and it is not approved.
NICE's draft guidance said the twice-yearly prevention shot would not be offered on the NHS in England, mainly over cost. Comments closed Sept 30, and a final decision meeting is set for Nov 3, 2026.
A once-daily pill of bictegravir and lenacapavir for adults whose HIV is already suppressed. In ARTISTRY-2 (574 people), 1.3% on Bixlenvo and 1.0% on Biktarvy had detectable virus at week 48, which met the goal of being no worse.
Among 626 adults switching from daily treatment, 0.3% on weekly islatravir + lenacapavir and 1.3% on their usual daily regimen had detectable virus at week 48. The weekly pill was no worse.
Researchers presented an "Essen patient", the first such case with hepatitis B too, and a "Kansas City patient", the youngest so far. Both got stem-cell transplants for cancer. These are conference reports, not peer-reviewed papers, and the transplants are too risky for anyone without life-threatening cancer.
In 607 adults switching from daily Biktarvy, no one on the weekly pill and 1 person (0.3%) on Biktarvy had detectable virus at week 48. Side-effect stop rates were similar (2.0% vs 1.7%).
Two Phase 3 trials, Daybreak 1 and Daybreak 2, began testing lenacapavir with the antibodies teropavimab and zinlirvimab. One compares it with Cabenuva injections. The other compares it with people's current daily pills.
Among 487 women who became pregnant during the trial, pregnancy outcomes and side effects were similar across groups. The drug reached breast milk, but babies' blood levels were very low. The authors say the data support faster access for pregnant and breastfeeding women.
68 men who had started ART early in infection stopped treatment after two long-acting antibodies or a placebo. At 20 weeks, 75% on antibodies had no rebound, compared with 11% on placebo. This is a remission study, not a cure.
A 63-year-old man got a transplant for myelodysplastic syndrome (a blood cancer) from his brother, who carries two copies of the HIV-blocking CCR5Δ32 mutation. He stopped ART 2 years later. At 4 years after the transplant, no intact HIV was found in blood or gut.
Pooling two trials with 8,660 people, twice-yearly lenacapavir led to a large drop in new infections compared with daily PrEP pills, about 14 fewer per 1,000 people. Injection-site reactions were more common.
Treatment controls HIV but doesn't cure it. Prevention (PrEP) protects people who don't have HIV. The newest options are about taking medicine less often.
A combination of HIV medicines. It lowers the virus until tests can't detect it, protects the immune system, and prevents sexual spread. The CDC recommends it for everyone with HIV.
Injections given by a clinician every month or every 2 months instead of daily pills, for people 12 and older whose HIV is already undetectable and who have no resistance to either drug.
A once-daily two-drug pill for switching. In two Phase 3 trials (ARTISTRY-1 and ARTISTRY-2) it kept the virus suppressed about as well as the regimens people were already taking.
In two Phase 3 trials, switching to one pill a week worked as well as daily treatment at 48 weeks. The makers plan to apply for approval. It is not approved yet.
In a Phase 2 trial, 1 of 53 people had detectable virus at 26 weeks, similar to daily pills. Only people whose virus was highly sensitive to both antibodies could join. Phase 3 trials started July 2026.
For people who don't have HIV. In PURPOSE 1, none of 2,134 women on twice-yearly lenacapavir got HIV. In PURPOSE 2, 2 of 2,179 participants did. These shots prevent HIV. They don't treat it.
| Treatment | For | What it does |
|---|---|---|
| Daily combination ART | Everyone with HIV | Keeps the virus suppressed. Undetectable means no sexual spread. |
| Cabotegravir + rilpivirine injections (Cabenuva) | People 12+ already suppressed | Clinic injections every 1 or 2 months instead of daily pills. |
| Newer switch pills: Bixlenvo, Idvynso | Adults already suppressed | Two-drug daily pills. Idvynso (doravirine + islatravir) was approved Apr 20, 2026. |
| Lenacapavir (Sunlenca) | Adults with multidrug-resistant HIV | Added to other HIV medicines when the current regimen is failing. |
| PrEP: daily pills, Apretude, Yeztugo | People without HIV who are at risk | Prevents HIV. An HIV test is needed before starting and before each shot. |
No supplement or natural product treats or cures HIV. Some can make HIV medicines work less well. We rate each by the strength of evidence.
HIV.gov strongly encourages it to lower heart-disease risk and help mood and sleep. A Cochrane review found aerobic exercise appears safe and may improve fitness.
Smoking's health risks are even higher for people with HIV, and quitting brings major, immediate benefits.
A Cochrane review found no consistent clinical benefit from routine use, but they make sense when there is a known deficiency or a poor diet.
Interacts with some HIV drugs and lowered antiretroviral levels in studies. Avoid it unless your HIV doctor says otherwise.
Some forms lowered levels of certain HIV medicines in a systematic review. Ask your pharmacist before taking them.
No product cures HIV. Replacing ART with remedies lets the virus come back and damage the immune system.
Be careful: calcium, iron, zinc, vitamin C and multivitamins can lower the levels of some HIV medicines. Timing can matter, so tell your doctor or pharmacist about everything you take, and never stop HIV treatment on your own.
Centers recognized for expertise in this condition, and communities of people living with it.
Home to one of the NIH's Centers for AIDS Research. The Hope Clinic at Emory is a listed site in PURPOSE 2, the Phase 3 trial of twice-yearly lenacapavir for prevention.
An NIH Center for AIDS Research site and a listed site in the PURPOSE 2 trial.
An NIH Center for AIDS Research site. Its Sexual Health Research Clinic is a listed site in the PURPOSE 2 trial.
An NIH Center for AIDS Research site. Its AntiViral Research Center is a listed site in the PURPOSE 2 trial.
A listed site in PURPOSE 1, the Phase 3 prevention trial in young women, and in ISLEND-2, the Phase 3 trial of the once-weekly treatment pill.
A listed site in ISLEND-2, the Phase 3 trial of the once-weekly islatravir + lenacapavir pill.
These are centers recognized for expertise in this condition, not a ranking, and Cure Checker does not endorse or rate any facility. Outcomes depend on the individual. Ask your doctor which center fits your situation.
A diagnosis can feel isolating, and stigma is still real. These groups connect people who understand. Most are free.
Search by location for HIV testing sites, care services and other support near you.
Visit ↗Round-the-clock discussion boards, including forums for women and for friends and family. Posts are public, searchable and can't be deleted, so don't use a name that identifies you.
Visit ↗A blog community where women across the gender spectrum share their experiences of living with HIV.
Visit ↗The UK HIV charity offers a helpline, groups and workshops, counselling and an online community for people living with HIV.
Visit ↗One-to-one peer support and groups for people living with HIV, including women's, over-50s and gay men's programs.
Visit ↗Many private groups exist. This link searches Facebook (a login is required). Think about privacy before joining, since group names can reveal your status.
Search Facebook ↗Before you join: support groups share experiences, not medical advice. Check anything about treatment with your doctor. Protect your privacy, and never share passwords or financial details. Cure Checker isn't affiliated with these groups.
Daily ART is used worldwide. In 2025, 32.1 million people were on treatment. Long-acting shots for treatment and prevention are approved in fewer places, and approval doesn't always mean public funding.
| Treatment | U.S. | EU | UK | Canada | Japan | S. Korea | China | Australia | Switz. |
|---|---|---|---|---|---|---|---|---|---|
| Lenacapavir every 6 months (Yeztugo / Yeytuo)Prevention (PrEP) | Approved 2025 | Approved 2025 | Approved 2025 | Approved 2026 | — | — | — | — | — |
| Cabotegravir every 2 months (Apretude)Prevention (PrEP) | Approved 2021 | Approved 2023 | NICE: limited | — | — | — | — | — | — |
| Cabotegravir + rilpivirine (Cabenuva / Vocabria + Rekambys)Long-acting treatment | Approved 2021 | Approved 2020 | — | Approved 2020 | — | — | — | — | — |
| Bictegravir + lenacapavir (Bixlenvo)Daily switch pill | Approved 2026 | — | — | — | — | — | — | — | — |
| Doravirine + islatravir (Idvynso)Daily switch pill | Approved 2026 | — | — | — | — | — | — | — | — |
No HIV infections occurred among 2,134 women given lenacapavir. A 2026 follow-up looked at women who became pregnant during the trial.
The Phase 3 trial ran at 100 sites in 14 countries and territories, including Argentina, Australia, Japan, South Africa, Switzerland and Thailand.
The WHO recommends twice-yearly lenacapavir as an extra PrEP option, with rapid HIV tests to make long-acting PrEP easier to deliver.
HIV (human immunodeficiency virus) attacks the immune cells that help the body fight infection. The body can't get rid of it on its own. Without treatment it can lead to AIDS, the most advanced stage.
Live numbers and the newest entries from the world's main trial registries and medical databases. Most of this loads fresh each time you open the page.
Loading live data from ClinicalTrials.gov…
Loading…
Loading…
Loading…
| Medicine | Brand | FDA application | Original approval |
|---|
From Drugs@FDA via FDA's openFDA service. Some older brands are missing from FDA's open data, and newly approved drugs can take a few weeks to appear. An approval may be for a different disease than this one.
The WHO's ICTRP gathers trials from registries worldwide, including China, Japan, India, Iran, Australia and Brazil. Cochrane CENTRAL and OpenMD don't allow automated access, so they're linked here for you to search directly.
These organizations give money directly to people living with HIV, toward costs such as medicines, rent or bills. Funds are limited and rules vary, so contact each one directly.
Selected applicants receive up to $500 for health care, housing or whatever they most need. Applications were closed on October 6, 2026 while the group raises more money. You can sign up for its emails to hear when they reopen.
See the fund ↗Social workers help plan for medical and money needs, and the Fund's emergency aid can help with basic living costs such as housing, utilities and health care. You must show several years of entertainment-industry earnings and a real financial need.
See the program ↗One-time help with an emergency cost that welfare offices and other sources won't cover. You apply by email or post with proof of income and costs and a doctor's confirmation of HIV. Help is not guaranteed, and past costs usually aren't covered.
See the program (German) ↗Quick financial help once other public and private help has been used up. An HIV advice centre or hospital social worker applies for you and passes the money on.
See the fund ↗Helps pay for FDA-approved HIV medicines, up to $2,100. It does not cover people with only private insurance. The fund was listed as open on October 6, 2026, but funds open and close as money allows.
Check fund status ↗Grants toward copays, coinsurance, deductibles and insurance premiums. The fund was closed on October 6, 2026; the page lets you sign up to hear when it reopens.
Check fund status ↗Before you apply: Cure Checker does not run, verify or endorse these organizations, and being listed is not a promise of help. Funds are limited and rules change, so confirm eligibility and details with each organization. Be careful of anyone who asks for payment up front or for your bank login to 'release' a grant.
Everything this report is based on, grouped by section. Checked October 4, 2026.
Not individually cited: that HIV infects CD4 cells and integrates into their DNA, which reflects the established medical literature. "About ten" cured or in long-term remission is IrsiCaixa's April 2026 count, and the "Essen" and "Kansas City" cases come from conference presentations reported by aidsmap (via EATG), not peer-reviewed papers. Counts differ between sources, and a 2025 Nature paper counted six documented cures before its own case. The Oslo patient's age is 63 in the published paper, while the IrsiCaixa release says 62. The Daybreak 1 and 2 names come from a Gilead release. The two ClinicalTrials.gov records don't list those names. Canada's lenacapavir approval year comes from a CATIE article dated June 4, 2026, which gives no exact approval date. The UK lenacapavir approval date comes from a news report of the MHRA decision. We could not open the MHRA's own page. The "NICE: limited" cell for cabotegravir PrEP means NICE recommended it in October 2025 for a narrow group, as reported by HIV i-Base. All "—" cells in the approvals table are unverified. EU dates are the EMA "marketing authorisation issued" dates. Gilead's release gives Aug 26, 2025 for Yeytuo, and we use the EMA date. A Reddit HIV community is not listed because we could not open Reddit to confirm one is current. Expert care centers: there is no single official designation for HIV care. The four U.S. entries are NIH-funded Centers for AIDS Research (CFAR) sites that are also listed sites in the registered PURPOSE 2 trial. The two others are listed sites in registered Phase 3 trials. Most people get HIV care from local clinics, which the HIV.gov locator can help find. Financial help: checked October 6, 2026, mostly with a headless browser. The Deutsche AIDS-Stiftung page is in German and we summarized it in translation. TotalAssist (where PAN Foundation's copay funds moved in 2026) blocked a second check, so its closed status comes from the first reading that day. The Entertainment Community Fund's earnings rule comes from its general financial assistance FAQ. Left out: the Terrence Higgins Trust hardship fund and CHIVA (their pages could not be opened), local programs that pass on Ryan White or HOPWA government money, and foundations that fund only organizations. HealthWell and The Assistance Fund listed no HIV fund.